Targacept, which is developing a new class of drugs for the treatment of nervous system disorders, released pricing terms for its upcoming IPO on Friday. The company plans to offer 6.25 million shares at a proposed price range of $11 to $13, resulting in an estimated market cap of $244 million. Deutsche Bank Securities and Pacific Growth Equities are the lead managers on the deal. The company has filed to be listed on the NASDAQ under the ticker TRGT.
